Top Qs
Timeline
Chat
Perspective
RDS03-94
Dopamine reuptake inhibitor related to modafinil being developed for stimulant use disorder From Wikipedia, the free encyclopedia
Remove ads
RDS03-94, or RDS3-094, is an atypical dopamine reuptake inhibitor that was derived from the wakefulness-promoting agent modafinil.[1][2][3][4]
Remove ads
It has substantially higher affinity and potency in terms of dopamine transporter (DAT) inhibition than modafinil (Ki = 39.4 nM vs. 8,160 nM) whilst retaining the atypical DAT blocker profile of modafinil.[1][2] However, RDS03-94 also has high affinity for the sigma σ1 receptor (Ki = 2.19 nM).[2]
RDS03-94 shows some reversal of tetrabenazine-induced motivational deficits in animals and hence may have the capacity to produce pro-motivational effects.[5][6] However, it appears to be less effective than certain other related agents, like JJC8-088.[6][5]
RDS03-94 is under development for the treatment of psychostimulant use disorder.[1] The drug was first described in the scientific literature in 2020.[1][2]
Remove ads
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads